Pioneer Plus导管在下肢慢性完全闭塞腔内血运重建中的安全性与有效性
该回顾性研究纳入2011年7月至2018年9月单中心116例患者共135例次下肢慢性完全闭塞(CTO)介入手术,评估Pioneer Plus导管辅助下的院内及30天结局。结果显示手术成功率为87.4%,无器械相关并发症,操作者经验是手术成功的唯一相关因素。
要点
- Pioneer Plus导管辅助下肢CTO介入手术成功率达87.4%。
- 未观察到假性动脉瘤、血管穿孔或动静脉瘘等器械相关并发症。
- 操作者经验是手术成功的唯一相关因素(P < .0001)。
核心结论
- Pioneer Plus导管用于下肢CTO开通安全有效,但需进一步研究患者和操作者因素以优化结局。
研究设计与样本
- 回顾性研究,纳入2011年7月至2018年9月单中心116例患者共135例次连续手术,由8名不同经验水平的操作者完成。
主要发现
- 总体手术成功率为87.4%(118/135例次)。
- 未观察到器械相关并发症,如假性动脉瘤、血管穿孔或动静脉瘘。
- 手术相关并发症包括穿刺点血肿(5.2%)、大出血(0.7%)、假性动脉瘤(0.7%)、远端栓塞(1.5%)和急性动脉血栓形成(1.5%)。
- 30天主要不良肢体事件发生率为5.9%,包括截肢(0.7%)、再干预(4.4%)和急性肢体缺血(0.7%)。
- 操作者经验是手术成功的唯一相关因素(P < .0001),经验>25台器械操作者的成功率≤95.8%。
关键数值与推荐
- 手术成功定义为器械相关疗效结局,成功率为87.4%。
- 操作者经验水平>25台器械部署时,成功率≤95.8%。
临床怎么用
- Pioneer Plus导管可安全用于下肢CTO的开通,尤其适用于股浅动脉和腘动脉CTO。
- 操作者经验与手术成功相关,经验积累有助于提高成功率。
局限性
- 回顾性单中心设计,样本量有限,可能存在选择偏倚。
- 需进一步研究以识别患者和操作者层面的因素以优化结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Our aim was to evaluate the efficacy and safety outcomes of the Pioneer Plus catheter (Philips, San Diego, Calif) and report the in-hospital and 30-day outcomes of lower extremity chronic total occlusion (CTO) interventions assisted by the Pioneer Plus catheter. In addition, we explored the factors associated with procedural success. METHODS: We conducted a retrospective review of 135 consecutive procedures in 116 patients from July 2011 to September 2018 performed by eight operators with various levels of experience at a high-volume center where the Pioneer Plus catheter was used for lower extremity CTO. The patient demographics, preprocedural symptoms, preprocedural testing results, procedural setting, and angiography findings were abstracted. The outcomes were divided into device-related and procedure-related outcomes. Device-related efficacy outcome included procedural success. Device-related safety outcomes included device-related complications. Procedure-related outcomes included procedure-related complications, 30-day major adverse cardiovascular events, and 30-day major adverse limb events. We conducted univariate comparisons of the provider, patient, and procedural characteristics stratified by procedural success. RESULTS: Procedural success was observed in 118 procedures overall (87.4%), and success rates ≤95.8% were observed for operators with an experience level of >25 devices deployed. No device-related complications, such as pseudoaneurysm formation, vessel perforation, or arteriovenous fistula formation, were observed. The Pioneer Plus catheter was mostly often used for CTO in the superficial femoral and popliteal arteries. Overall, the procedure-related complications included access site hematoma (5.2%), major bleeding (0.7%), pseudoaneurysm formation (0.7%), distal embolization (1.5%), and acute arterial thrombosis (1.5%). The 30-day major adverse limb events included index limb unplanned amputation (0.7%), index limb reintervention (4.4%), and index limb acute limb ischemia (0.7%) and occurred in 5.9% of the procedures. The only factor associated with procedural success was operator experience (P < .0001). CONCLUSIONS: The results from the present study have shown that Pioneer Plus catheter use is safe and effective when used to cross lower extremity CTO. However, further investigation is needed to identify patient- and provider-level factors to optimize patient outcomes.
引用
- Sheikh AB, Llanos-Chea F, Jelani QU, et al. Safety and efficacy outcomes of the Pioneer Plus catheter in endovascular revascularization of lower extremity chronic total occlusions. J Vasc Surg. 2021. PMID: 33592298. doi:10.1016/j.jvs.2021.01.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。